嵌合抗原受体T细胞疗法（CAR-T）是一种新兴的治疗难治性血液恶性肿瘤的方法。CAR-T治疗后未计划的急诊就诊增多，因此需要一个整合的护理模式，以便早期识别其特定并发症。本研究是在三级医疗中心进行的前瞻性观察性研究。通过治疗提供者的普遍登记，将CAR-T患者（n=17）纳入研究登记表。调查员通过设置弹出式通知的CAR-T信息警告，将这些患者标记在急诊排队时进行提醒。医疗记录被回顾了90天，目的是检查未计划的就诊情况、并发症以及以患者为导向的结果。接受CAR-T治疗的患者在治疗后的7天内经常出现毒副作用。这通常是温和的，并在住院环境中发生。医疗记录的审查发现了五起未计划的急诊就诊（被认定为CAR-T治疗后的就诊），并非直接归因于特定的毒副作用。如果要在更广泛的门诊护理模式下普遍使用CAR-T治疗，就需要建立一个标准化的急诊护理模式来识别特定的并发症。 © 2023 Australasian College for Emergency Medicine.

Chimeric antigen receptor T-cell (CAR-T) therapy is an emerging treatment for refractory hematologic malignancy. Unplanned ED presentations following CAR-T present the increasing need for an integrated model of care that allows for the early recognition of its specific complications.This is a prospective observational study at a tertiary centre. CAR-T patients (n = 17) were universally enrolled into a study registry by treating providers. These patients were flagged by investigators to trigger a pop-up notification CAR-T information warning at ED triage. Medical records were reviewed 90 days for unplanned presentations, complications and patient-oriented outcomes.Patients receiving CAR-T frequently encountered toxicity within 7 days of therapy. This was typically mild and occurred in an inpatient setting. Medical record review revealed five unplanned ED presentations (that were recognised as post CAR-T) and not directly attributable to specific toxicities.If CAR-T therapy is to be used more widely especially in an outpatient model of care, a standardised ED model of care for recognition of specific complications is needed.© 2023 Australasian College for Emergency Medicine.